Inflammatory Bowel Disease News and Research

Latest Inflammatory Bowel Disease News and Research

Early diagnosis of colorectal cancer can minimize treatment side effects in survivors

Renato Lenzi, M.D., medical oncologist at The University of Texas MD Anderson Cancer Center and colon cancer survivor, knows only too well how important preventive methods are to beating colorectal cancer. After all, a routine colonoscopy saved his life.

24 Mar 2011

NephRx receives new U.S. patent for NX002 to treat IBD

NephRx Corporation today announced issuance of a new U.S. patent for use of its novel growth factor peptide NX002 as a potential treatment for inflammatory bowel disease.

24 Mar 2011

Stress can change balance of gut bacteria

Stress can change the balance of bacteria that naturally live in the gut, according to research published this month in the journal Brain, Behavior, and Immunity.

22 Mar 2011

NasVax reports positive results from Phase 2a trial of oral immunotherapy for non-alcoholic steatohepatitis

NasVax announces the success of a Phase 2a clinical trial of a new oral immunotherapy for non-alcoholic steatohepatitis (NASH), an inflammatory disease associated with fatty liver disease and the metabolic syndrome.

21 Mar 2011

Asthma an diabetes go hand in hand: Research

A new study has found that people with asthma may have a higher risk of developing diabetes and heart disease. The study looked at the relationship between asthma and four other inflammatory conditions.

21 Mar 2011

FibroGen, Astellas advance FG-4592 to phase 2b development for treatment of anemia in chronic kidney disease

FibroGen, Inc., today announced that FibroGen and partner Astellas Pharma Inc. advanced FG-4592 (Astellas designation ASP1517), an investigational anemia therapy, to phase 2b development for treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis.

18 Mar 2011

Children and youth with IBD have 25% lower aerobic fitness levels

Children and adolescents growing up with inflammatory bowel disease are less fit than their peers, says a study by researchers at McMaster University and the McMaster Children's Hospital.

17 Mar 2011

New study: Positive outcomes from gene therapy trial in patients with Parkinson's

A multi-center gene therapy trial for patients with advanced Parkinson's disease demonstrated reduced symptoms of the progressive movement disorder, according to a new study published in Lancet Neurology.

17 Mar 2011

Specialists to provide update on latest advancements in surgical field at UCSD conference

The Department of Surgery at the University of California, San Diego School of Medicine will host the 34th San Diego Postgraduate Assembly in Surgery. The event will take place March 17 to 19, 2011 at the Omni San Diego Hotel.

14 Mar 2011

NIH awards Avaxia Phase I SBIR grant to develop novel antibody therapeutic for celiac disease

Avaxia Biologics, Inc., a privately-held biotech company using its proprietary platform technology to develop orally-active antibody therapeutics for the treatment of gastrointestinal diseases, announced today that it has been awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health (NIH), to support the development of a novel antibody therapeutic for celiac disease.

11 Mar 2011

Despite aspirin therapy, specific inflammatory pathways may influence risk of colorectal cancer

The reduced risk of colorectal cancer associated with taking aspirin or other nonsteroidal anti-inflammatory drugs may be confined to individuals already at risk because of elevations in a particular inflammatory factor in the blood.

10 Mar 2011

Santarus commences SAN-300 Phase I clinical study to treat inflammatory diseases

Santarus, Inc., a specialty biopharmaceutical company, today announced that it has initiated a Phase I clinical study with SAN-300, its anti-VLA-1 antibody.

10 Mar 2011

Blood biomarker may help decide intake of aspirin or NSAIDs for reduction of cancer risk

The reduced risk of colorectal cancer associated with taking aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs) may be confined to individuals already at risk because of elevations in a particular inflammatory factor in the blood.

10 Mar 2011

North Shore-LIJ launches new prenatal quality initiative

Having a child is a life event that is equal parts magic and fear. Will the baby be healthy? Will labor and delivery pose challenges? Are there ways to reduce the risk for adverse events? Hospital obstetrical units face these questions round-the-clock.

8 Mar 2011

Scientists identify regulatory T cells responsible for limiting immune response

Scientists from the Walter and Eliza Hall Institute have identified the key immune cell population responsible for regulating the body's immune response.

6 Mar 2011

Pfizer's ORAL Sync Phase 3 study of tofacitinib in moderate-to-severe RA meets primary endpoints

Pfizer Inc. today announced that the ORAL Sync Phase 3 study of tofacitinib, formerly known as tasocitinib, an investigational, novel, oral JAK inhibitor, being studied in moderate-to-severe rheumatoid arthritis, met its primary endpoints by showing statistically significant changes versus placebo in reducing signs and symptoms of RA, as measured by ACR20 response rates at six months; in improving physical function, as measured by mean change in HAQ DI at three months; and in reaching DAS28-4 <2.6 at six months.

5 Mar 2011

NorthShore receives $1.5 million gift to establish center for the study of complex diseases

NorthShore University HealthSystem (NorthShore) Foundation has received a $1.5 million gift for the creation of the Center for the Study of Complex Diseases. The development of the Center, which is being established within the NorthShore Research Institute, is made possible through a generous gift by Mr. and Mrs. Richard L. Keyser of Glencoe, Ill., through the Keyser Family Research Fund.

4 Mar 2011

Pluristem's PLX cells exhibit potential to treat accidental and intentionally induced muscle injuries

Pluristem Therapeutics, Inc. and the Berlin-Brandenburg Center for Regenerative Therapies (BCRT), in cooperation with the Charite - University of Medicine in Berlin,today announced the results of a pre-clinical study demonstrating that the local administration of PLX cells following muscle injury resulted in significant improvement in the recovery of muscle function when compared with the control group. This

2 Mar 2011

Final data from 4SC vidofludimus ENTRANCE Phase IIa trial against IBD presented at ECCO IBD Conference

4SC AG, a drug discovery and development company focused on autoimmune and cancer indications, announces the final data from the ENTRANCE Phase IIa trial in inflammatory bowel disease with vidofludimus, an oral inhibitor of interleukin-17 release and DHODH, including the secondary endpoints comprising the analysis of CDAI and CAI disease scores, change of prednisolone intake and threshold doses, safety, pharmacokinetics and biomarkers.

28 Feb 2011

Researchers identify probiotic bacterial strain that may treat ulcers caused by H. pylori

Researchers from Spain have identified a strain of probiotic bacteria that may be useful in treating ulcers caused by Helicobacter pylori. They report their findings in the February 2011 issue of the journal Applied and Environmental Microbiology.

25 Feb 2011

Inflammatory Bowel Disease News and Research

Latest Inflammatory Bowel Disease News and Research

Early diagnosis of colorectal cancer can minimize treatment side effects in survivors

NephRx receives new U.S. patent for NX002 to treat IBD

Stress can change balance of gut bacteria

NasVax reports positive results from Phase 2a trial of oral immunotherapy for non-alcoholic steatohepatitis

Asthma an diabetes go hand in hand: Research

FibroGen, Astellas advance FG-4592 to phase 2b development for treatment of anemia in chronic kidney disease

Children and youth with IBD have 25% lower aerobic fitness levels

New study: Positive outcomes from gene therapy trial in patients with Parkinson's

Specialists to provide update on latest advancements in surgical field at UCSD conference

NIH awards Avaxia Phase I SBIR grant to develop novel antibody therapeutic for celiac disease

Despite aspirin therapy, specific inflammatory pathways may influence risk of colorectal cancer

Santarus commences SAN-300 Phase I clinical study to treat inflammatory diseases

Blood biomarker may help decide intake of aspirin or NSAIDs for reduction of cancer risk

North Shore-LIJ launches new prenatal quality initiative

Scientists identify regulatory T cells responsible for limiting immune response

Pfizer's ORAL Sync Phase 3 study of tofacitinib in moderate-to-severe RA meets primary endpoints

NorthShore receives $1.5 million gift to establish center for the study of complex diseases

Pluristem's PLX cells exhibit potential to treat accidental and intentionally induced muscle injuries

Final data from 4SC vidofludimus ENTRANCE Phase IIa trial against IBD presented at ECCO IBD Conference

Researchers identify probiotic bacterial strain that may treat ulcers caused by H. pylori

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Inflammatory Bowel Disease News and Research

Latest Inflammatory Bowel Disease News and Research

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in